NovaBay Pharmaceuticals Inc. saw its stock surge by 60% after a $6 million investment and the appointment of new CEO David Lazar, positioning the company for future growth and innovation in the pharmaceutical industry.
NovaBay Pharmaceuticals Inc is a biopharmaceutical company poised to make significant strides in the topical anti-infective market with its innovative solutions and strategic focus on addressing pressing healthcare needs.